Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ZTS

Is Zoetis Stock Underperforming the Dow?

Zoetis's shares are trailing the broader Dow Jones index, yet analysts still project upside, signaling confidence in the company’s long-term recovery potential.

Barchart

Zoetis Osteoarthritis Pain Franchise Needs A Reset: Analyst

As the animal health industry navigates a rapidly evolving landscape, companies are increasingly challenged to maintain their competitive edge through innovation and strategic adaptation.

Benzinga

Zoetis Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Pressured Amid Valuation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.12%. December E-mini S&P futures (ESZ25 ) are down -0.74%, and December E-mini Nasdaq futures...

Barchart

Stocks Retreat on Valuation Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -0.97%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.29%. December E-mini S&P futures (ESZ25 ) are down -0.95%, and December E-mini Nasdaq futures...

Barchart

Is Zoetis Stock Underperforming the Nasdaq?

While Zoetis has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Zoetis Stock Will Climb or Sink?

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

Benzinga

Here's What to Expect From Zoetis’ Next Earnings Report

Zoetis is scheduled to report its second-quarter earnings next month, and analysts are forecasting a modest single-digit increase in profitability.

Barchart

Is Zoetis Stock Underperforming the S&P 500?

Despite Zoetis’ recent underperformance relative to the S&P 500, analysts remain highly optimistic about the stock’s prospects.

Barchart

Is Wall Street Bullish or Bearish on Zoetis Stock?

Despite the animal healthcare giant Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a highly optimistic outlook on the stock’s prospects.

Barchart

Earnings Preview: What To Expect From Zoetis’ Report

Zoetis is set to announce its first-quarter results in the upcoming month, and analysts expect a modest single-digit growth in earnings.

Barchart

How Is Zoetis’ Stock Performance Compared to Other Pet Care Stocks?

Zoetis has notably lagged behind other pet care stocks over the past year, yet analysts remain strongly bullish on the stock’s prospects.

Barchart

3 Pet Industry Stocks Benefiting from the Boom in Animal Care

With a rising number of pet owners and increased spending, the pet industry is demonstrating strong growth potential. Investors seeking to capitalize on this trend could grab shares of Zoetis (ZTS), Chewy (CHWY), and Trupanion (TRUP). Read on….

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Are Wall Street Analysts Bullish on Zoetis Stock?

While Zoetis has underperformed relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

StockNews.com

3 Pet Industry Stocks Profiting from Animal Lovers

The pet industry is expected to witness significant growth, driven by the surging demand for pet products and healthcare requirements from animal lovers. Thus, it could be wise to add fundamentally sound pet stocks Zoetis (ZTS), Chewy (CHWY), and PetMed Express (PETS) to your portfolio for substantial gains. Read more.

Barchart

Zoetis’ Quarterly Earnings Preview: What You Need to Know

Animal health giant Zoetis is set to release its fourth-quarter results in the upcoming month and analysts expect a significant double-digit growth in earnings.

StockNews.com

Is Zoetis a Smart Investment in the Pharmaceuticals Sector?

Zoetis (ZTS) reported strong financial results for the last reported quarter. Amid the growing attention and concern on animal health and care, ZTS’ diverse product portfolio stands to benefit significantly from its continuous product innovations. So, should you buy this innovative pharmaceutical stock considering the current trends? Read more to…

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Healthcare Innovators with Analyst-Endorsed Upside

Healthcare innovators are gaining momentum as they address critical challenges in biotechnology, medical devices, and pharmaceuticals. Amid this backdrop, you might consider keeping an eye on three healthcare innovators, Zoetis (ZTS), Immatics N.V. (IMTX), and Esperion Therapeutics (ESPR), which have robust upside potential. Read on….

Barchart

Zoetis Stock: Is ZTS Underperforming the Healthcare Sector?

Zoetis has recently underperformed the broader healthcare sector, but analysts remain optimistic about its long-term growth prospects.

StockNews.com

Is Zoetis Leading the Charge in Animal Health Innovation?

Zoetis Inc. (ZTS) reported impressive results for the third quarter of 2024, with strong revenue growth across diverse regions. The company’s future growth prospects appears promising, fueled by solid demand for its product offerings, operational expansions, and effective capital allocation. So, let’s determine whether Zoetis is an ideal addition to…

Barchart

3 'Strong Buy' Cyclical Stocks to Scoop Up Now

Brokerage firm Morgan Stanley is bullish on cyclical stocks.

Barchart

What Are Wall Street Analysts' Target Price for Zoetis Stock?

Zoetis has significantly underperformed the broader market over the past year, yet analysts remain bullish on the stock’s prospects.

Barchart

Zoetis' Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

Barchart

Zoetis's Q3 2024 Earnings: What to Expect

Zoetis will release its third-quarter earnings next month, and analysts expect a single-digit profit surge.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.